Effects of Vasoactive Intestinal Polypeptide on Isolated Rat Urinary Bladder Smooth Muscle

Erol, Kevser; Ulak, Güner; Dönmez, T.; Cingi, M. I.; Alpan, Recep Serdar; Özdemir, Musa

doi:10.1159/000282414

Cited by 17 publications

(12 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…VIP has been shown to relax urinary bladder from human (Uckert et al, 2002) or pig (Hernandez et al, 2006), and contract or produce no effects on urinary bladder from the rat (Erol et al, 1992;Igawa et al, 1993). These contradictory findings might be attributable to species differences (Uckert et al, 2002) and differential VIP receptor distribution.…”

Section: Discussionmentioning

confidence: 99%

“…VIP is a member of the glucagon/secretin superfamily of hormones (Dickinson et al, 1999) and acts through two high affinity receptors, the VPAC 1 and VPAC 2 receptors (Harmar et al, 1998). VIP exerts, species-specific, excitatory or inhibitory actions in neural pathways controlling micturition and these functions may be altered with neural injury, disease or inflammation (Erol et al, 1992;Igawa et al, 1993;Uckert et al, 2002;Hernandez et al, 2006). VIP-immunoreactivity has been demonstrated throughout the neural pathways of the lower urinary tract de Groat, 1989, 1992;Wanigasekara et al, 2003).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Urinary Bladder Function and Somatic Sensitivity in Vasoactive Intestinal Polypeptide (VIP)−/− Mice

et al. 2008

View full text Add to dashboard Cite

Vasoactive intestinal polypeptide (VIP) is an immunomodulatory neuropeptide widely distributed in neural pathways that regulate micturition. VIP is also an endogenous anti-inflammatory agent that has been suggested for the development of therapies for inflammatory disorders. In the present study, we examined urinary bladder function, hindpaw and pelvic sensitivity in VIP -/-and littermate wildtype controls. We demonstrated increased bladder mass and fewer but larger urine spots on filter paper in VIP -/-mice. Using cystometry in conscious, unrestrained mice, VIP -/-mice exhibited increased void volumes and shorter intercontraction intervals with continuous intravesical infusion of saline. No differences in transepithelial resistance or water permeability were demonstrated between VIP -/-and WT mice; however, an increase in urea permeability was demonstrated in VIP -/-mice. With the induction of bladder inflammation by acute administration of cyclophosphamide (CYP), an exaggerated or prolonged bladder hyperreflexia, hindpaw and pelvic sensitivity were demonstrated in VIP -/-mice. The changes in bladder hyperreflexia and somatic sensitivity in VIP -/-mice may reflect increased expression of neurotrophins and/or or proinflammatory cytokines in the urinary bladder. Thus, these changes may further regulate the neural control of micturition.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Urinary Bladder Function and Somatic Sensitivity in Vasoactive Intestinal Polypeptide (VIP)−/− Mice

et al. 2008

View full text Add to dashboard Cite

show abstract

“…VIP exerts, species-specific, excitatory or inhibitory actions in neural pathways controlling micturition and these functions may be altered with neural injury, disease or inflammation (Erol et al, 1992; Igawa et al, 1993; Uckert et al, 2002; Hernandez et al, 2006). A number of diverse and conflicting roles for VIP have been demonstrated in the urinary bladder from numerous species.…”

Section: 2 Pacap/vip and Associated Receptors Signaling In The Lutmentioning

confidence: 99%

“…A number of diverse and conflicting roles for VIP have been demonstrated in the urinary bladder from numerous species. VIP has been shown to relax urinary bladder from human (Uckert et al, 2002) or pig (Hernandez et al, 2006), and contract or produce no effects on urinary bladder from the rat (Erol et al, 1992; Igawa et al, 1993). These contradictory findings might be attributable to species differences (Uckert et al, 2002) and differential VIP receptor distribution (Table 19.1).…”

Section: 2 Pacap/vip and Associated Receptors Signaling In The Lutmentioning

confidence: 99%

Neuropeptides in Lower Urinary Tract Function

Arms

Vizzard

2011

Urinary Tract

View full text Add to dashboard Cite

Numerous neuropeptide/receptor systems including vasoactive intestinal polypeptide, pituitary adenylate cyclase-activating polypeptide, calcitonin gene-related peptide, substance P, neurokinin A, bradykinin, and endothelin-1 are expressed in the lower urinary tract (LUT) in both neural and non-neural (e.g., urothelium) components. LUT neuropeptide immunoreactivity is present in afferent and autonomic efferent neurons innervating the bladder and urethra and in the urothelium of the urinary bladder. Neuropeptides have tissue-specific distributions and functions in the LUT and exhibit neuroplastic changes in expression and function with LUT dysfunction following neural injury, inflammation and disease. LUT dysfunction with abnormal voiding including urinary urgency, increased voiding frequency, nocturia, urinary incontinence and pain may reflect a change in the balance of neuropeptides in bladder reflex pathways. LUT neuropeptide/receptor systems may represent potential targets for therapeutic intervention.

show abstract

“…VIP has been shown to relax urinary bladder from human (Uckert et al, 2002) or pig (Hernandez et al, 2006), and contract or produce no effects on urinary bladder from the rat (Igawa et al, 1993;Erol et al, 1992). These contradictory findings might be attributable to species differences (Uckert et al, 2002).…”

Section: Vip Functions In the Lower Urinary Tractmentioning

confidence: 99%

Expression of Phosphorylated cAMP Response Element Binding Protein (p-CREB) in Bladder Afferent Pathways in VIP−/− Mice with Cyclophosphamide (CYP)-Induced Cystitis

et al. 2008

View full text Add to dashboard Cite

The expression of phosphorylated cAMP response element binding protein (pCREB) in dorsal root ganglia (DRG) with and without CYP-induced cystitis (150 mg/kg, i.p; 48 hr) was determined in VIP −/− and wildtype (WT) mice. p-CREB-immunoreactivity (IR) was determined in bladder (Fastblue) afferent cells. Nerve growth factor (NGF) bladder content was determined by ELISAs. Basal expression of pCREB-IR in DRG of VIP −/− mice was (p ≤ 0.01) greater in L1, L2, L5-S1 DRG compared to WT mice. CYP treatment in WT mice increased (p ≤ 0.05) pCREB-IR in L1, L2, L5-S1 DRG. CYP treatment in VIP −/− mice (p ≤ 0.01) increased (p ≤ 0.01) p-CREB-IR in L6-S1 DRG compared to WT with CYP. In WT mice, bladder afferent cells (20-38%) in DRG expressed pCREB-IR under basal conditions. With CYP, pCREB-IR increased in bladder afferent cells (60-65%; L6-S1 DRG) in WT mice. In VIP −/− mice, bladder afferent cells (12-58%) expressed pCREB-IR under basal conditions and CYP increased pCREB expression (78-84%) in L6-S1 DRG. Urinary bladder NGF expression in VIP −/− mice under basal conditions or after cystitis was significantly greater than WT. Detrusor smooth muscle thickness was significantly increased in VIP −/− mice. Bladder NGF expression may contribute to differences in pCREB expression.

show abstract

Effects of Vasoactive Intestinal Polypeptide on Isolated Rat Urinary Bladder Smooth Muscle

Cited by 17 publications

References 12 publications

Urinary Bladder Function and Somatic Sensitivity in Vasoactive Intestinal Polypeptide (VIP)−/− Mice

Urinary Bladder Function and Somatic Sensitivity in Vasoactive Intestinal Polypeptide (VIP)−/− Mice

Neuropeptides in Lower Urinary Tract Function

Expression of Phosphorylated cAMP Response Element Binding Protein (p-CREB) in Bladder Afferent Pathways in VIP−/− Mice with Cyclophosphamide (CYP)-Induced Cystitis

Contact Info

Product

Resources

About